Literature DB >> 27523595

Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage.

Daniel E Spratt1, Hebert A Vargas2, Zachary S Zumsteg3, Jennifer S Golia Pernicka2, Joseph R Osborne2, Xin Pei3, Michael J Zelefsky4.   

Abstract

BACKGROUND: Clinical trials evaluating the benefit of pelvic radiotherapy (PRT) in the radiotherapeutic management of patients with higher-risk prostate cancer have limited the superior field border to the S1/S2 or L5/S1 interspace. However, imaging and surgical series have demonstrated a high frequency of prostatic lymph node (LN) drainage beyond these landmarks.
OBJECTIVE: To determine the patterns of radiographically defined abdominopelvic LN failures and their potential implications for PRT field design. DESIGN, SETTING, AND PARTICIPANTS: During 1992-2008, 2694 patients with localized prostate cancer were treated with prostate/seminal vesicle-only radiotherapy without PRT. Some 156 patients had their first failure within the abdominopelvic LNs, of whom 60 had isolated failures within the pelvic LNs. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: A radiologist reviewed all imaging and mapped each LN failure to a template consisting of 34 abdominopelvic LN stations. RESULTS AND LIMITATIONS: The median follow-up was 8.9 yr. Of patients who experienced first recurrence in the pelvic LNs (n=60), the common iliac station was involved in 55% (n=33) of patients, including 10% (n=6) who had isolated common iliac failures. Use of a PRT field superior border of L5/S1 would fully cover only 42% of the first recurrences among these patients. Extending the field to cover the common iliac stations would increase coverage to 93% of recurrences. The presence of T3/T4 disease and omission of androgen-deprivation therapy both independently conferred an approximate fivefold increase in the likelihood of having a common iliac LN failure. Use of imaging as a surrogate for LN involvement is the primary study limitation.
CONCLUSIONS: Pelvic LN failures frequently occur superior to the commonly used L5/S1 landmark for PRT coverage, and use of ADT may be protective of more superior LN failures. The current RTOG 0924 trial is evaluating the benefit of PRT with extended superior coverage to L4/5 when possible, which, according to our data, should significantly improve the coverage of potential sites of failure. PATIENT
SUMMARY: We looked at lymph node recurrence patterns after external beam radiotherapy of the prostate in men who did not have their lymph nodes treated. We found that there was a high incidence of pelvic lymph node recurrences above the internal and external iliac lymph node regions. Therefore, the current field recommendation for pelvic lymph nodes that stops at the superior border of the internal and external iliac vessels provides inadequate coverage of common sites of cancer recurrence, namely the common iliac lymph nodes.
Copyright © 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Metastatic pattern; Pelvic lymph nodes; Prostate cancer; Radiotherapy

Mesh:

Year:  2016        PMID: 27523595      PMCID: PMC5571898          DOI: 10.1016/j.eururo.2016.07.043

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  20 in total

1.  Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores.

Authors:  Alberto Briganti; Alessandro Larcher; Firas Abdollah; Umberto Capitanio; Andrea Gallina; Nazareno Suardi; Marco Bianchi; Maxine Sun; Massimo Freschi; Andrea Salonia; Pierre I Karakiewicz; Patrizio Rigatti; Francesco Montorsi
Journal:  Eur Urol       Date:  2011-11-07       Impact factor: 20.096

2.  Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06.

Authors:  S O Asbell; J M Krall; M V Pilepich; H Baerwald; W T Sause; G E Hanks; C A Perez
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-12       Impact factor: 7.038

3.  Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer.

Authors:  Zachary S Zumsteg; Daniel E Spratt; Paul B Romesser; Xin Pei; Zhigang Zhang; Marisa Kollmeier; Sean McBride; Yoshiya Yamada; Michael J Zelefsky
Journal:  J Urol       Date:  2015-07-10       Impact factor: 7.450

4.  Predictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy.

Authors:  Daniel E Spratt; Zachary S Zumsteg; Xin Pei; Paul B Romesser; Josh Yamada; Marisa A Kollmeier; Kaitlin Woo; Zhigang Zhang; Michael J Zelefsky
Journal:  Prostate       Date:  2014-10-18       Impact factor: 4.104

5.  Influence of 3D-CRT pelvic irradiation on outcome in prostate cancer treated with external beam radiotherapy.

Authors:  C C Pan; K Y Kim; J M G Taylor; P W McLaughlin; H M Sandler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-08-01       Impact factor: 7.038

6.  Relating dose outside the prostate with freedom from failure in the Dutch trial 68 Gy vs. 78 Gy.

Authors:  Marnix G Witte; Wilma D Heemsbergen; Román Bohoslavsky; Floris J Pos; Abrahim Al-Mamgani; Joos V Lebesque; Marcel van Herk
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-12-11       Impact factor: 7.038

7.  RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer.

Authors:  Colleen A F Lawton; Jeff Michalski; Issam El-Naqa; Mark K Buyyounouski; W Robert Lee; Cynthia Menard; Elizabeth O'Meara; Seth A Rosenthal; Mark Ritter; Michael Seider
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-10-22       Impact factor: 7.038

8.  Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer.

Authors:  Daniel E Spratt; Xin Pei; Josh Yamada; Marisa A Kollmeier; Brett Cox; Michael J Zelefsky
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-07-12       Impact factor: 7.038

9.  Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation.

Authors:  Daniel E Spratt; Michael J Evans; Brian J Davis; Michael G Doran; Man Xia Lee; Neel Shah; John Wongvipat; Kathryn E Carnazza; George G Klee; William Polkinghorn; Donald J Tindall; Jason S Lewis; Charles L Sawyers
Journal:  Cancer Res       Date:  2015-10-02       Impact factor: 12.701

10.  Androgen receptor signaling regulates DNA repair in prostate cancers.

Authors:  William R Polkinghorn; Joel S Parker; Man X Lee; Elizabeth M Kass; Daniel E Spratt; Phillip J Iaquinta; Vivek K Arora; Wei-Feng Yen; Ling Cai; Deyou Zheng; Brett S Carver; Yu Chen; Philip A Watson; Neel P Shah; Sho Fujisawa; Alexander G Goglia; Anuradha Gopalan; Haley Hieronymus; John Wongvipat; Peter T Scardino; Michael J Zelefsky; Maria Jasin; Jayanta Chaudhuri; Simon N Powell; Charles L Sawyers
Journal:  Cancer Discov       Date:  2013-09-11       Impact factor: 39.397

View more
  12 in total

1.  Dose-escalated pelvic radiotherapy for prostate cancer in definitive or postoperative setting.

Authors:  Giulio Francolini; Giulia Stocchi; Beatrice Detti; Vanessa Di Cataldo; Alessio Bruni; Luca Triggiani; Andrea Emanuele Guerini; Rosario Mazzola; Francesco Cuccia; Matteo Mariotti; Viola Salvestrini; Pietro Garlatti; Simona Borghesi; Gianluca Ingrosso; Rita Bellavita; Cynthia Aristei; Isacco Desideri; Lorenzo Livi
Journal:  Radiol Med       Date:  2021-11-30       Impact factor: 3.469

Review 2.  Intensity-modulated radiotherapy for prostate cancer.

Authors:  Ben W Fischer-Valuck; Yuan James Rao; Jeff M Michalski
Journal:  Transl Androl Urol       Date:  2018-06

3.  Risk-adapted moderate hypofractionation of prostate cancer : A prospective analysis of acute toxicity, QOL and outcome in 221 patients.

Authors:  Andreas Schörghofer; Michael Groher; Josef Karner; Andrea Kopp; Gerhard Kametriser; Thomas Kunit; Josef Holzinger; Felix Sedlmayer; Frank Wolf
Journal:  Strahlenther Onkol       Date:  2019-05-28       Impact factor: 3.621

Review 4.  Combined Modality Therapies for High-Risk Prostate Cancer: Narrative Review of Current Understanding and New Directions.

Authors:  Benjamin A Greenberger; Victor E Chen; Robert B Den
Journal:  Front Oncol       Date:  2019-11-29       Impact factor: 6.244

5.  The Distribution of Pelvic Nodal Metastases in Prostate Cancer Reveals Potential to Advance and Personalize Pelvic Radiotherapy.

Authors:  Irina Filimonova; Daniela Schmidt; Sina Mansoorian; Thomas Weissmann; Hadi Siavooshhaghighi; Alexander Cavallaro; Torsten Kuwert; Christoph Bert; Benjamin Frey; Luitpold Valentin Distel; Sebastian Lettmaier; Rainer Fietkau; Florian Putz
Journal:  Front Oncol       Date:  2021-01-08       Impact factor: 6.244

Review 6.  Angiogenesis and immune checkpoint dual blockade in combination with radiotherapy for treatment of solid cancers: opportunities and challenges.

Authors:  Lingling Zhu; Xianzhe Yu; Li Wang; Jiewei Liu; Zihan Qu; Honge Zhang; Lu Li; Jiang Chen; Qinghua Zhou
Journal:  Oncogenesis       Date:  2021-07-10       Impact factor: 7.485

7.  Nodal recurrence patterns on PET/CT after RTOG-based nodal radiotherapy for prostate cancer.

Authors:  C P Liskamp; M L Donswijk; H G van der Poel; E E Schaake; W V Vogel
Journal:  Clin Transl Radiat Oncol       Date:  2020-02-26

8.  Feasibility of Dose Escalating [18F]fluciclovine Positron Emission Tomography Positive Pelvic Lymph Nodes During Moderately Hypofractionated Radiation Therapy for High-Risk Prostate Cancer.

Authors:  Andrew M McDonald; Samuel J Galgano; Jonathan E McConathy; Eddy S Yang; Michael C Dobelbower; Rojymon Jacob; Soroush Rais-Bahrami; Jeffrey W Nix; Richard A Popple; John B Fiveash
Journal:  Adv Radiat Oncol       Date:  2019-06-19

9.  Haute Couture or Ready-to-Wear? Tailored Pelvic Radiotherapy for Prostate Cancer Based on Individualized Sentinel Lymph Node Detection.

Authors:  Anne-Victoire Michaud; Benoit Samain; Ludovic Ferrer; Vincent Fleury; Mélanie Doré; Mathilde Colombié; Claire Dupuy; Emmanuel Rio; Valentine Guimas; Thierry Rousseau; Maelle Le Thiec; Grégory Delpon; Caroline Rousseau; Stéphane Supiot
Journal:  Cancers (Basel)       Date:  2020-04-10       Impact factor: 6.639

10.  PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.

Authors:  A De Bruycker; A Spiessens; P Dirix; N Koutsouvelis; I Semac; N Liefhooghe; A Gomez-Iturriaga; W Everaerts; F Otte; A Papachristofilou; M Scorsetti; M Shelan; S Siva; F Ameye; M Guckenberger; R Heikkilä; P M Putora; A Zapatero; A Conde-Moreno; F Couñago; F Vanhoutte; E Goetghebeur; D Reynders; T Zilli; P Ost
Journal:  BMC Cancer       Date:  2020-05-12       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.